Validity of the MAGIC study: Sufficient for recommendations?

Hepato-Gastroenterology

Volumn 60, Issue 127, 2013, Pages 1822-1824

  Bauer, Katrin ^a   Porzsolt, Franz ^b   Henne Bruns, Doris ^b  

^a Kempten Hospital   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cancer of the esophagogastric junction; Gastric cancer; Perioperative chemotherapy

Indexed keywords

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; GASTRECTOMY; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893960044     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13116     Document Type: Article

References (19)

1. Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ: Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg 1993;80:1015-1018. (Pubitemid 23261584)
2. Robert-Koch-Institut: http://www.krebsdaten.de/Krebs/DE/Content/ Krebsarten/Magenkrebs/magenkrebs-node.html
3. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725-730.
4. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35(7):1059-1064. (Pubitemid 29339187)
5. Paoletti X, Oba K, Burzykowski T, et al.: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303(17):1729-1737.
6. Moehler M, Al Batran SE, Andus T, et al.: S3-Leitlinie "Magenkarzinom" Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. Z Gatroenterol 2011; 49:461-531.
7. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 335(1):11-20.
8. Gastinger I, Lippert H, Meyer L, Ridwelksi K: Qualitä tssicherungsstudie Magenkarzinom (Primärtumor), An-Institut der Universität Magdeburg, Zwischenergebnisse der Jahre 2007 bis 2010.
9. de Martel C, Franceschi S: Infections and cancer: established associations and new hypotheses. Crit Rev OncolHematol 2009; 70(3):183-194.
10. Hartgrink HH, van de Velde CJ, Putter H, et al.: Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomized FAMTX trial. Eur J SurgOncol 2004;30:643-649. (Pubitemid 39060735)
11. Taves D: Minimization: A new method of assigning patients to treatment and control groups.ClinPharmacolTherapeut1974; 15(5):443-453.
12. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31:103-115.
13. Scott NW, McPherson GC, Ramsay CR, Campbell MK: The method of minimization for allocation to clinical trials. a review. Control Clin Trials 2002;23:662-674. (Pubitemid 36005476)
14. Power DG, Schattner MA, Gerdes H, et al.: Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg 2009; 208:173-178.
15. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-1608. (Pubitemid 15062653)
16. Lauren T: The two histological main types of gastric carcinoma. ActaPatholMicrobiolScand 1965;64:34.
17. Songun I, Putter H, Kranenbarg EM, et al.: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol2010; 11:439-449.
18. Lachin JM: Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000;5:526.
19. Porzsolt F, Eisemann M, Habs M, Wyer P: Form follows function: pragmatic controlled trials (PCTs) have to answer different questions and require different designs than randomized controlled trials (RCTs). J Publ Health 2013 in press.